Dr. Daniel Michael Geynisman, MD

Dr. Geynisman practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Geynisman's NPI, 1437343597, was assigned on August 31, 2007. Dr. Geynisman graduated from University of Pittsburgh School of Medicine in 2006. Dr. Geynisman holds Pennsylvania license MD436806.

Dr. Geynisman's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Geynisman's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Geynisman is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Geynisman to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Geynisman practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Geynisman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Geynisman is licensed in Pennsylvania.

CMS data shows 654 Medicare services from Dr. Geynisman across 5 procedure codes in 2024, all of them office visits, for 235 Medicare patients. Medicare paid $59,190 for them.

CMS counts 235 Medicare patients who saw Dr. Geynisman in 2024. The largest group is 75 to 84, with 110 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Geynisman's median patient age at 74, with 8% women.

In 2024, Dr. Geynisman wrote 1,892 Medicare Part D claims for 185 patients. 65% of them were for generic drugs. CMS names the drug for 1,613 of them, across 27 drugs with 11 or more claims each, at $7,443,218 in total drug cost. In 2023, CMS named 1,106 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Geynisman for performance year 2024, reported as part of a group. Dr. Geynisman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Geynisman as offering telehealth.

Dmand AI links 130 papers to Dr. Geynisman, published from 2012 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Urinary Bladder Neoplasms. Dr. Geynisman has published most often in Eur Urol. Dr. Geynisman's most frequent co-authors are Elizabeth R. Plimack, MD, Pooja Atul Ghatalia, MD and Matthew Rion Zibelman, MD.

Dmand AI links Dr. Geynisman to 8 clinical trials, 6 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Carcinoma, Transitional Cell. Fox Chase Cancer Center sponsors the most, 3.

CMS Open Payments shows 196 general payments to Dr. Geynisman from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Exelixis Inc. paid the most, $48,734. It also lists 1 research payment totaling $3,222 in 2019.

Dr. Geynisman graduated from University of Pittsburgh School of Medicine in 2006.